Table 2.

Susceptibility to bicuculline methiodide-induced seizures in mice deficient in IL-1 receptor-type I: effect of intrahippocampal infusion of recombinant IL-1Ra

	No mice with seizures		Onset, min		Duration, min
	Clonic	Tonic	Clonus	Tonus	Clonus	Tonus
Wild type	15/15	15/15	2.6  ± 0.2	5.8  ± 0.6	118.2  ± 7.3	4.3  ± 0.7
Wild type + IL-1Ra	15/15	15/15	5.6  ± 0.5*	12.1  ± 1.3*	102.4  ± 6.8	1.1  ± 0.1*
Knockout	10/10	10/10	3.3  ± 0.3†	7.5  ± 0.6*	108.0  ± 10.4	2.7  ± 0.3
Knockout + IL-1Ra	10/10	9/10	3.7  ± 0.8†	7.4  ± 0.7*	134.0  ± 11.0	3.3  ± 0.5

Data are the mean ± S.E.M. Fractions represent the number of 129/SV PasIco mice showing clonic or tonic seizures on the total number of mice. Bicuculline methiodide was injected at a dose of 0.97 nmol in 0.5 μl unilaterally in the dorsal hippocampus. IL-1Ra (0.3 nmol in 0.5 μl) was injected at the same site as bicuculline, 5 min before the convulsant. Recombinant IL-1Ra significantly delayed the onset of clonic and tonic seizures and reduced the duration of tonic convulsions in wild-type littermate mice, whereas it was ineffective in IL-1R type I-deficient mice. Note the delayed onset of clonic and tonic seizures in IL-1R type I-deficient mice (knockout) compared to wild-type littermate mice. Wild-type and knockout mice were injected with heat-inactivated cytokine before bicuculline.  

^†, P < 0.05; *, P < 0.01 vs. wild type by Tukey's test.